Burden of thromboembolism, disease progression, and phlebotomy among polycythemia vera patients in the United States: a systematic literature review
Polycythemia vera patients face substantial blood clots and progression risks annually, underscoring the need for better treatments beyond current phlebotomy approaches.
This systematic review of 35 US-based PV studies quantifies the substantial burden: 1.4-6.5 annual TEs per 100 patients, myelofibrosis progression in up to 20%, and phlebotomy-linked QoL impairment, highlighting significant unmet treatment need. The review was funded by Takeda Pharmaceuticals — relevant conflict of interest for interpreting conclusions about treatment gaps.
What the study was
- Study design
- Systematic literature review (35 studies)
- Population
- Polycythemia vera patients in the United States
- Category
- Public Health
- Maturity
- Validated
- Journal
- Expert Rev Hematol
Why it surfaced
Systematic evidence quantification of PV burden; relevant to MPN watchlist. Takeda-funded (conflict of interest noted).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.